Summit Trail Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Summit Trail Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$287K	Sell	5,077 -1,126	-18%	-$65.7K	﹤0.01%	1311
2025 Q4	$369K	Buy	6,203 +686	+12%	+$37.3K	0.01%	1167
2025 Q3	$299K	Buy	+5,517	New	+$316K	﹤0.01%	1207
2018 Q1	–	Sell	-555	Closed	-$51K	–	583
2017 Q4	$51K	Buy	+555	New	+$48.3K	0.01%	811

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Summit Trail Advisors's BMRN Position: Q1 2026 in Review

Summit Trail Advisors reduced its BioMarin Pharmaceuticals (BMRN) stake by 18% in Q1 2026, selling an estimated $65.7K and leaving 5,077 shares worth $287K. The position accounts for ﹤0.01% of the portfolio, ranked #1311.

Summit Trail Advisors first reported a position in BMRN in Q4 2017 and has held it in 4 quarters since. The position peaked at $369K in Q4 2025. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Summit Trail Advisors held 5,077 shares of BioMarin Pharmaceuticals worth $287K as of Q1 2026.
Summit Trail Advisors sold 1,126 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $65.7K.
BioMarin Pharmaceuticals made up ﹤0.01% of Summit Trail Advisors's portfolio in Q1 2026, its #1311 holding.
Summit Trail Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2017 and has held it in 4 quarters since.
Summit Trail Advisors's BioMarin Pharmaceuticals position peaked at $369K in Q4 2025.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.